Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
因醉鞭名马幌
发表于 2024-12-4 17:04:09
129
0
0
On December 3rd, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: CRDA®) We have obtained approval from the National Medical Products Administration (NMPA) of China to combine platinum based chemotherapy as neoadjuvant therapy and continue to use pembrolizumab monotherapy as adjuvant therapy after surgery for stage II, IIIA, and IIIB non-small cell lung cancer patients who can be surgically resected. Previously in China, pembrolizumab had obtained three indications for advanced non-small cell lung cancer.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- This US funded enterprise has clarified its confidence and direction for development in China through the CIIE
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
- AbbVie Dual Anti Cancer New Drug Declares for Market in China
- A sharp drop of 87%! Maserati will only sell over 30 units in China in September! Has the 'Sports Car Queen' fallen from grace?
- Honda accelerates its electrification layout in China, with joint ventures intensively deploying electric vehicles
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- The CEO of the world's fourth largest car company, Stellantis, has resigned and adjusted the person in charge of related business in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
-
"대적전 창시자 장충모: 인텔이 AI 물결을 따라잡지 못한 삼성의 문제는 경영전략에 있지 않다"12월 9일, 대적전 창시자 장충모의 자서전 전집의 신간 발표회가 중국 대만에서 개최되였다.행사장에서 경쟁사인 인텔 ...- 西西里柠檬2017
- 그저께 14:46
- Up
- Down
- Reply
- Favorite
-
12월 11일 CNN에 따르면 엘론 머스크의 순자산은 4000억 달러에 달해 사상 처음으로 이 관문을 돌파했다. 머스크의 재산은 그의 우주 탐사 기술 회사와 관련이 있는 200억 달러 가까이 다시 늘어난 것으로 알려졌다 ...- 真不是我干的的
- 5 시간전
- Up
- Down
- Reply
- Favorite
-
미국 동부 시간으로 월요일, 미국 주식 3대 지수는 집단적으로 하락하여 마감 마감되었는데, 나지는 0.62%, S & P500 지수는 0.61%, 지수는 0.54% 하락했다. 나스닥 중국 진룽지수는 8.54% 상승해 인기 있는 중국계 ...- 强绝商爸摇
- 그저께 13:58
- Up
- Down
- Reply
- Favorite
-
샤오펑자동차 웨이보 12월 11일 소식에 따르면 샤오펑 P7 + 는 출시 4주 만에 10000대의 샤오펑 P7 + 를 정식 인도했다.- 崔炫俊献
- 어제 12:18
- Up
- Down
- Reply
- Favorite
